The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive
symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The
investigators hypothesize the following for the present study:
A single dose of ketamine will induce a rapid, robust and sustained reduction in depressive
symptoms in subjects with a comorbid major depressive episode and alcohol dependence relative
to placebo as defined by change in Hamilton Depression Rating Scale total scores at 72 hours
post infusion.
A single dose of ketamine can be delivered safely, with minimal adverse events or
complications, in subjects with a comorbid major depressive episode and alcohol dependence.